San Bruno Center for Dental Medicine – San Bruno – Perfect 5 Star Review by Brent W. – Video

Posted on by


San Bruno Center for Dental Medicine - San Bruno - Perfect 5 Star Review by Brent W.
http://sanbrunocosmeticdentist.com/ 650-539-3179 San Bruno Center for Dental Medicine San Bruno Reviews Excellent Review Dr. Parker was concerned with my comfort during the procedure,...

By: Improved Results

Read more here:

San Bruno Center for Dental Medicine - San Bruno - Perfect 5 Star Review by Brent W. - Video

Roche to Acquire Majority Stake in Cancer Genetic Test Maker Foundation Medicine

Posted on by

CAMBRIDGE, Mass. (TheStreet) -- Foundation Medicine (FMI) will become majority-owned by Roche (RHHBY) as part of a $1 billion-plus strategic partnership to expand the use of genetic testing in cancer drug research and treatment, the companies announced today.

Roche's acquired stake in Foundation Medicineis priced at $50 per share, more than double the company's Friday closing price of $23.93. Foundation Medicine will continue to operate independently.

Must Read: Jim Cramer's Five Best Stock Picks for the Biotech Sector

The investment and strategic collaboration between Roche and Foundation Medicine was announced on the eve of the closely followed J.P. Morgan Healthcare Conferencein San Francisco.

Foundation Medicine analyzes the genetic signature of tumors to help doctors match patients with the optimal cancer treatment -- both approved drugs or clinical trials of experimental therapies. The company's two commercially available tests analyze solid tumors and blood-based cancers to find specific genetic mutations.

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Read more:

Roche to Acquire Majority Stake in Cancer Genetic Test Maker Foundation Medicine

Drug deal to target cancer: CEO

Posted on by

Roche Holding has agreed to buy a majority stake in U.S.-based molecular and genomic analysis firm Foundation Medicine for up to $1.18 billion, in a move to bolster the Swiss drugmaker's personalized cancer treatments.

Dr. Michael J. Pellini, chief executive of Foundation, told CNBC on Monday the deal can accelerate a move into precision medicine for oncology.

"It's an important day for patients battling cancer," he said in a "Squawk Box" interview, noting that Foundation helps doctors understand cancer at its blueprint and then deploy targeted therapeutics.

Roche will pay $50 a share, or about $780 million, a premium of 109 percent to Foundation's closing price Friday. Roche will also invest $250 million in Foundation by acquiring newly issued shares.

As a result, Roche will own 52.4 percent to 56.3 percent of Foundation. The companies said the deal includes the potential for more than $150 million in additional funding by Roche.

Reuters contributed to this report.

Read the original here:

Drug deal to target cancer: CEO

Roche Takes Control of Innovative DNA Test Maker Foundation Medicine

Posted on by

A $1 billion deal for tests that can steer patients to the right drug.

The pharmaceutical giant Roche plans to spend $1 billion to acquire majority control of Foundation Medicine, a five-year old company that developed an innovative DNA test to match patients to specific cancer drugs.

We profiled Foundation in back in 2012 (see Foundation Medicine: Personalizing Cancer Drugs), highlighting how the spinout of the MIT-Harvard Broad Institute was one of the first to introduce tests to sequence the DNA of a tumor biopsy to pinpoint the exact mutations driving a persons tumor, and possibly steer treatment. At the time, we described Foundations pricey $5,800 cancer test, called FoundationOne, this way:

Foundations business model hinges on the convergence of three recent developments: a steep drop in the cost of decoding DNA, much new data about the genetics of cancer, and a growing effort by pharmaceutical companies to develop drugs that combat the specific DNA defects that prompt cells to become cancerous.

Foundation tried something new and important. But it turns out that its hard to make money in diagnostics, and the technology of DNA testing is developing and changing very quickly, too. All that helps explain why the company agreed to sell a little over half its shares to Roche, which sells more cancer drugs than anyone. As the New York Times says today:

Roche, which is the worlds largest seller of cancer drugs, said it would use some insights from that testing to develop drugs and better tailor them for specific groups of patients. In addition, Roche, which also has a huge diagnostics business, will sell Foundations tests outside the United States.

I think it just brings personalized health care in oncology to a new level, Daniel ODay, who runs Roches pharmaceutical business, said in an interview.

The Foundation deal appears to be the largest in a series of takeovers by Roche of innovative diagnostics firms. A few years back, Roche tried and failed to acquire Illumina, the sequencing machine company whose technology underlies the explosion in DNA research. But Roche is finding no shortage of companies that are willing to sell. During the last twelve months, it bought Ariosa, a prenatal testing company, as well as Genia Technologies, which Roche paid $350 million for, and Bina Technologies, which develops bioinformatics software.

Foundations test is used to analyze a tumor for several hundred cancer-linked genes. As we reported in 2013, an early and famous customer for this technology was Apple founder Steve Jobs (see Steve Jobs Left a Legacy on Personalized Medicine):

It turns out that Jobs was one of the first peopleand certainly the best-knownto try this kind of all-in genetic strategy to beat cancer. As recounted in Walter Isaacsons biography of the Apple CEO, Jobs spent $100,000 to learn the DNA sequence of his genome and that of the tumors killing him. Jobs was jumping between treatments and hoped DNA would provide clues about where to turn next.

View post:

Roche Takes Control of Innovative DNA Test Maker Foundation Medicine

$1.8B drug deal to target cancer at genetic level

Posted on by

Roche Holding has agreed to buy a majority stake in U.S.-based molecular and genomic analysis firm Foundation Medicine for up to $1.18 billion, in a move to bolster the Swiss drugmaker's personalized cancer treatments.

Dr. Michael J. Pellini, chief executive of Foundation, told CNBC on Monday the deal can accelerate a move into precision medicine for oncology.

"It's an important day for patients battling cancer," he said in a "Squawk Box" interview, noting that Foundation helps doctors understand cancer at its blueprint and then deploy targeted therapeutics.

Roche will pay $50 a share, or about $780 million, a premium of 109 percent to Foundation's closing price Friday. Roche will also invest $250 million in Foundation by acquiring newly issued shares.

As a result, Roche will own 52.4 percent to 56.3 percent of Foundation. The companies said the deal includes the potential for more than $150 million in additional funding by Roche.

Reuters contributed to this report.

See the rest here:

$1.8B drug deal to target cancer at genetic level

Allen-Medical Campus rail station to be closed for a month

Posted on by

Metro Rails Allen-Medical Campus Station, soon to be integrated into the new University at Buffalo Medical School, will be closed for about a month, tentatively beginning Feb. 16 as construction proceeds on the new $375 million complex.

Thomas George, director of public transit for the Niagara Frontier Transportation Authority, said planners decided to close one of the Buffalo subways busiest stations for an extended period rather than on an occasional basis to ensure the safety of commuters while heavy equipment erects structural steel and major construction continues.

The biggest reason for this is personal safety, he said. As theyre putting up structural steel, we just wont have the ability to have passengers in there.

And rather than closing it on and off during the spring, we said lets just get it done all in one period, he added. Were much happier moving in this direction.

In the meantime, George said, shuttle buses sponsored by UB as part of the project will transport the Medical Campus workers using the subway from Summer-Best Station, just north of the closed facility. Buses will pick up passengers arriving on Metro Rail trains at Summer-Best and take them throughout the Medical Campus, he said, as well as passengers boarding outside the shuttered Allen-Medical Campus Station.

Trains will continue to operate through Allen-Medical Campus, George said, but nobody will be able to enter or exit.

Already, much of the old subway station has been demolished to make way for its inclusion into the ground floor of the new medical school, resembling similar stations integrated into large buildings like those in New York City or Washington. While the below-ground boarding platforms at Allen-Medical Campus will be largely unaffected, the above-ground section will be drastically altered as it serves as the first floor of the new seven-floor medical school.

The station serves about 2,700 passengers daily, but Medical Campus officials project that ridership will grow significantly as employment there grows to levels approaching 20,000. New housing also has been sprouting around Metro Rail stations, with city officials attributing much of that growth to Medical Campus workers seeking a true urban lifestyle that does not require cars.

The new station also will feature a concession area a first for the Metro Rail system that George envisions as a grab and go food service and newsstand or possibly something more elaborate.

Once we issue a request for proposals, well see who wants to have a presence there, he said.

View post:

Allen-Medical Campus rail station to be closed for a month

Dr. Rick Sacra Returning to Liberia to Help Rebuild

Posted on by

By Chelsea Rice

Boston.com Staff | 01.12.15 | 7:24 PM

Its been almost five months since Dr. Richard Sacra was released from Nebraska Medical Center in Omaha after a 20-day battle with the deadly Ebola virus. But hes ready to get back to work. Sacra contracted Ebola in Liberia at the end of August after working in a hospital clinic for medical missionaries under SIM. On Thursday, Jan. 15, Sacra will return again to Liberia.

This time though, it will be different.

When Sacra decided to return to Liberia in August (he had lived and worked there off and on for 15 years previously), he was answering the call of a struggling hospital clinic in crisis. Dr. Kent Brantly had fallen ill after contracting the deadly virus, and nurse Nancy Writebol was being evacuated the day Sacra landed in Monrovia, the district at the center of the outbreak where their ELWA Hospital was located. The hospital was closed because of the lack of doctors, so Sacra was flying to Liberia to fill the vacuum needed to keep the hospital open.

Advertisement - Continue Reading Below

It was a crisis momentthe hospital was closed and we were trying to get it reopened, Sacra said in an interview at UMass Medical School on Monday in Worcester. Now its more like there are already people running with the ball, and Im just hopping in to try to give it all a little push.

Its a little less stressful this time, to say the least. Sacra is there to lend a hand and help relieve some of SIMs overburdened staff who have been working around the clock to address all of the patient needs. You see, this isnt even an Ebola clinic. This is your typical hospital. But because of Ebola and a fractured health care system, people havent been able to receive care for other illnesses and issues such as diabetes or high blood pressure. Sick children and pregnant women havent been able to see a doctor in months because of the daunting and overwhelming Ebola crisis.

Sacra said hes hoping to do some work with the medical school there as well. Unfortunately, many of the faculty in the area medical school have left the country or lost their lives treating Ebola patients. While the threat of contracting Ebola itself presented a stressful element to Sacras first trip in August, this time Sacra is preparing himself for the absences--the faces he wont see, the colleagues who have lost their lives battling for the lives of their patients, and their own.

I know its going to be difficult seeing friends who have lost loved ones, said Sacra. But I need to give them support for what theyve been through. For instance, theres a doctor who passed away in October, and Im going to see his wifethats going to be heavy.

See the original post here:

Dr. Rick Sacra Returning to Liberia to Help Rebuild

Liberty Global (LBTYB) Downgraded From Buy to Hold

Posted on by

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. TheStreet Ratings quantitative algorithm evaluates over 4,300 stocks on a daily basis by 32 different data factors and assigns a unique buy, sell, or hold recommendation on each stock. Click here to learn more.

NEW YORK (TheStreet) -- Liberty Global (LBTYB) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+. TheStreet Ratings Team has this to say about their recommendation:

"We rate LIBERTY GLOBAL PLC (LBTYB) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, compelling growth in net income and revenue growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet."

Must Read: Warren Buffett's 25 Favorite Stocks

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Originally posted here:

Liberty Global (LBTYB) Downgraded From Buy to Hold

Liberty Coach, Emerald Luxury Coaches Teaming up for Tampa SuperShow

Posted on by

North Chicago, IL and Stuart, FL (PRWEB) January 12, 2015

When the doors to the Tampa RV SuperShow open on Wednesday, longtime Prevost conversion leader Liberty Coach will be joined by Emerald Luxury Coaches of Stephenville, Texas at Booth 100 of the Florida State Fairgrounds in Tampa.

Located just inside the Gate 1 entrance off U.S. 301, the two companies shared space is sure to draw plenty of traffic to the Prevost conversion display area with two distinctively different approaches to the art of motorcoach design.

On one hand theres Emerald, a relative newcomer to the Prevost field from John Walker, whose Outlaw Conversions is a world leader in horse trailer conversions. Emeralds coaches offer distinctively warm, homelike interiors, quality materials and impeccable craftsmanship, all for prices well below the industry average.

Then theres Liberty, the perennial Prevost sales leader for 2014, they chalked up an astounding 109 coach sales and universally regarded as the Rolls Royce of the industry. Year in and year out, SuperShow crowds flock to the Liberty booth to catch up on the latest and greatest in coach innovations. And this year, once again, they wont be disappointed.

Among the many new features Liberty is showcasing is a 65-inch UHD television in the lower bay entertainment center by far the largest set ever installed in a lower bay configuration. The new TV is standard equipment in both of the 2015 coaches Liberty will have on display at the show, which include the Verona Bedroom Superslide Edition (Stock No. 780) and the double slide Fairfax Edition (Stock No. 785). Also available for viewing will be Emerald Coach No. 5395, the very latest model from Emerald Luxury Coaches.

The shared SuperShow display is the latest development in the mutually beneficial relationship between the two companies, which began last spring when Liberty announced an agreement to provide sales and dealership services for Emerald Luxury Coaches. And for SuperShow attendees, its a great opportunity to see the very best of whats new in Prevost coach conversions from two of the most dynamic manufacturers both in the same booth.

With locations in Stuart, FL and North Chicago, IL, Liberty Coach has been providing legendary leadership in the luxury motor coach industry for over 40 years. For more information about Libertys custom Prevost motor coaches, please visit http://www.libertycoach.com or call 800-554-9877. Or stop by Booth 100 at the Tampa RV Supershow, January 14-18, at the Florida State Fairgrounds in Tampa.

Original post:

Liberty Coach, Emerald Luxury Coaches Teaming up for Tampa SuperShow